anco ash 2005 review acute leukemias feb 22, 2006 charles linker md
TRANSCRIPT
![Page 1: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/1.jpg)
ANCO ASH 2005 ReviewANCO ASH 2005 Review Acute Leukemias Acute Leukemias
Feb 22, 2006Feb 22, 2006
Charles LinkerCharles Linker MDMD
![Page 2: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/2.jpg)
Abstract # 43Abstract # 43Mini-allo for AMLMini-allo for AML
Herr et alHerr et alEBMT ReviewEBMT Review
![Page 3: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/3.jpg)
Mini-allo for AMLMini-allo for AMLEBMT RegistryEBMT Registry
n = 204
Age 58 (median)
Sib and MUD donors
Regimen - Flu/Bu, Flu/TBI
FU 13mo
1-yr TRM 15%
1-yr Rel 34%
1-yr LFS 50%
1-yr OS 62%
![Page 4: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/4.jpg)
Abstract # 47Abstract # 47Mini-allo for AMLMini-allo for AML
Shimoni et alShimoni et alTel Hashomer, IsraelTel Hashomer, Israel
![Page 5: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/5.jpg)
Mini-allo AMLMini-allo AMLIsraelIsrael
n = 67
Age > 55
Sib and MUD donors
Regimen - Flu/Bu
FU 22mo
2-yr TRM 8%
2-yr OS 47%
If CR1: 2-yr OS 80%, TRM 0%
![Page 6: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/6.jpg)
CALGB 100103
Phase II Study of mini-allo for AML CR1, age > 60
Study Chair: Steve DevineStudy Chair: Steve Devine
CTN co-chair: Sergio GiraltCTN co-chair: Sergio Giralt
![Page 7: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/7.jpg)
CALGB 100103Background - 1
• Poor results of chemotherapyPoor results of chemotherapy
• No signs of progress in chemotherapyNo signs of progress in chemotherapy
• New approaches are warrantedNew approaches are warranted
![Page 8: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/8.jpg)
CALGB 100103CALGB background data
• Analysis of 600 CALGB AML age > 60 with Analysis of 600 CALGB AML age > 60 with cytogeneticscytogenetics
CR 50%CR 50%
5-year OS 7% !!!5-year OS 7% !!!
Cytogenetics predictive of outcomeCytogenetics predictive of outcome
![Page 9: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/9.jpg)
AML CR1, age > 60DFS by Cytogenetics
Time (Years)
Probability of Remaining Disease-Free
0 5 10 15
0.0
0.2
0.4
0.6
0.8
1.0
<5 abnormalities (n=273)
>= 5 abnormalities (n=23)
P<0.001
< 5 Abnormalities
P<0.001
5 Abnormalities
![Page 10: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/10.jpg)
AML CR1, age > 60OS by Cytogenetics
![Page 11: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/11.jpg)
AML CR1, age > 60OS by Age
![Page 12: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/12.jpg)
CALGB 100103Background - 2
• Results in best group are still poor (n = 276)Results in best group are still poor (n = 276)
CR1CR1
Age 60-75Age 60-75
Receive first consolidation on randomized trialReceive first consolidation on randomized trial
• 2-year DFS 24%2-year DFS 24%
• 3-year DFS 17%3-year DFS 17%
![Page 13: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/13.jpg)
CALGB 100103Eligibility - 1
• AML CR1AML CR1Prior MDS, t-AML allowedPrior MDS, t-AML allowed
<< 2 cycles induction 2 cycles induction
<< 2 courses consolidation 2 courses consolidation
<< 6 months in CR1 6 months in CR1
exclude APL, prior MPDexclude APL, prior MPD
• Age 60-74Age 60-74
• Matched sibling or 10/10 MUD donorMatched sibling or 10/10 MUD donor
![Page 14: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/14.jpg)
CALGB 100103Eligibility - 2
• PS 0 - 2PS 0 - 2
• Adequate organ functionAdequate organ functionDLCODLCO > > 40% 40%
EF EF >> 30% 30%
Creatinine clearanceCreatinine clearance > > 40 40
Bili < 2.0Bili < 2.0
AST < 3x normalAST < 3x normal
![Page 15: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/15.jpg)
CALGB 100103 Preparative Regimen
• Fludarabine 30 mg/m2 x 5Fludarabine 30 mg/m2 x 5 days -7 to -3days -7 to -3
• Busulfan 0.8 mg/kg IV x 8Busulfan 0.8 mg/kg IV x 8 days -4 to -3days -4 to -3
• Thymoglobulin 2.5 mg/kg x 3Thymoglobulin 2.5 mg/kg x 3 days -4 to -2days -4 to -2
• Stem cell infusionStem cell infusion day 0day 0
![Page 16: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/16.jpg)
CALGB 100103 GVH Prophylaxis
• TacrolimusTacrolimus day - 2 to +90day - 2 to +90
• MTX 5 mg/m2MTX 5 mg/m2 days, +1, 3, 6, 11days, +1, 3, 6, 11
• Taper tacTaper tac day +90 to +150/+180 day +90 to +150/+180
![Page 17: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/17.jpg)
CALGB 100103 Statistics
• Primary objective 2-year DFS Primary objective 2-year DFS >> 35% 35%90% power to exclude DFS < 20%90% power to exclude DFS < 20%
• Accrual goal = 61Accrual goal = 61
• Stopping rules for TRMStopping rules for TRMAssume true TRM 20%Assume true TRM 20%Unacceptable TRM 40%Unacceptable TRM 40%
![Page 18: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/18.jpg)
CALGB 100103
• Currently active in CALGB Currently active in CALGB sib donors onlysib donors only
• Amendment in processAmendment in processAdd CTNAdd CTN
Add MUDAdd MUD
![Page 19: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/19.jpg)
Mini-allo for AML, age > 60
• Currently treatments work poorlyCurrently treatments work poorly
• Mini-allo is feasibleMini-allo is feasible
• Several pilot studies show DFS > 40%Several pilot studies show DFS > 40%
• Deserves testing in Group settingDeserves testing in Group setting
• CALGB 100103 is last chance for USA studyCALGB 100103 is last chance for USA study
![Page 20: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/20.jpg)
Abstract # 146Abstract # 146Ph+ ALLPh+ ALL
Dellanoy et alDellanoy et alGRALL, FranceGRALL, France
![Page 21: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/21.jpg)
Ph+ ALL,age > 55Ph+ ALL,age > 55TreatmentTreatment
• Pre-phasePre-phase
Prednisone x 1 week
• InductionInduction
CyDVP
Imatinib 600 x 2 mo
• ConsolidationConsolidation
10 blocks of chemo
2 x 2 mo imatinib
• CNS-PCNS-P
i.t. mtx + cranial RT
![Page 22: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/22.jpg)
Ph+ ALL, age > 55Ph+ ALL, age > 55ResultsResults
N = 30
Age 66 (58 - 78)
FU 15mo
CR 20/29 ( vs 6/21 historical control)
1-yr OS 71% (11% control)
1-yr EFS 57% (5% control)
![Page 23: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/23.jpg)
ASCT for high-risk ALLProtocol 9501 & SOC
10864200.0
0.2
0.4
0.6
0.8
1.0
EFS 44%
10/25/05YEARS
![Page 24: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/24.jpg)
Protocol 9501 SOC for Ph+Effect of Imatinib
10864200.0
0.2
0.4
0.6
0.8
1.0
Imatinib EFS 71%
pre-Imatinib EFS 20%
10/25/05YEARS
![Page 25: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/25.jpg)
Ph+ ALLPh+ ALLRole of ImatinibRole of Imatinib
• Plays major role in inductionPlays major role in inductionSafe to combine with chemotherapySafe to combine with chemotherapyIncreases remission rateIncreases remission rate
• Encouraging results post-remissionEncouraging results post-remission• May play role in transplantMay play role in transplant
Allo transplant is treatment of first choicePatients get to transplant in remission May reduce relapse rateASCT being tested in CALGB 10001
May allow PCR neg stem cells for ASCT
![Page 26: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/26.jpg)
Abstract # 150Abstract # 150Nelarabine for T-ALLNelarabine for T-ALL
Goekbuget et alGoekbuget et alGMALL, GermanyGMALL, Germany
![Page 27: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/27.jpg)
CALGB 19801CALGB 19801De Angelo et alDe Angelo et al
ASH #743 (2002)ASH #743 (2002)• Eligibility
T-ALL or T-LLRelapse or refractory
• TreatmentNelarabine (GW 506U) 1.5g/m2 days 1, 3, 5q3 weeks x 2 cyclesResponders may get additional 2 cycles
• Results10/38 CR (26%)MDCR 10mo1-yr DFS 40%
![Page 28: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/28.jpg)
NelarabineNelarabinePatients and TreatmentPatients and Treatment
• n = 53
• Age 31 (19 - 81)
• Disease category:
First relapse 36
Second relapse 7
Relapse after transplant 7
Refractory 3
• Treatment:
Nelarabine 1.5g/m2 days 1, 3, 5
![Page 29: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/29.jpg)
NelarabineNelarabineResultsResults
25/53 CR (47%)
19/25 Cr go to transplant
OS 16%
OS of CR 27%
![Page 30: ANCO ASH 2005 Review Acute Leukemias Feb 22, 2006 Charles Linker MD](https://reader035.vdocument.in/reader035/viewer/2022062408/56649f275503460f94c3f690/html5/thumbnails/30.jpg)
Nelarabine for T-ALLNelarabine for T-ALL
• Important new agentImportant new agent
• Good choice for relapseGood choice for relapse
• Should be tested up frontShould be tested up front